Mirvetuximab soravtansine is a FRα-targeting monoclonal antibody-drug conjugate, which was approved by the United States Food and Drug Administration (FDA) in 2022 for the treatment of FRα-positive platinum-resistant ovarian cancer [12]. The gene discussed is FOLR1; the disease is ovarian carcinoma.